Roth Capital Issues Positive Estimate for CLRB Earnings
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Roth Capital upped their Q2 2025 earnings estimates for shares of Cellectar Biosciences in a research report issued to clients and investors on Wednesday, June 11th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn ($0.12) per share for the quarter, up from […]
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Roth Capital upped their Q2 2025 earnings estimates for shares of Cellectar Biosciences in a research report issued to clients and investors on Wednesday, June 11th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn ($0.12) per share for the quarter, up from […]
